Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
 - EconoTimes)
NEW ORLEANS, March 10, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until May 8, 2017 to file lead plaintiff applications in a securities class action lawsuit against NantHealth, Inc. (Nasdaq:NH), if they purchased the Company’s securities pursuant or traceable to the Company’s initial public offering on June 1, 2016 (the “IPO”) or between June 1, 2016 and March 6, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the Central District of California.
What You May Do
If you purchased securities of NantHealth and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 8, 2017.
About the Lawsuit
NantHealth and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 6, 2017, an article was published alleging NantHealth’s CEO’s donation to the University of Utah required the university to spend $10 million on work performed by NantHealth, an arrangement which enabled NantHealth to inflate by more than 50 percent the number of test orders it reported to investors in 2016. The article also quoted two tax experts stating that the deal appeared to violate federal tax rules governing charitable donations.
On this news, the price of NantHealth’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
